The present invention relates to: a polymerizable compound represented by a formula (I); a polymerizable composition comprising the polymerizable compound and an initiator; a polymer obtained by polymerizing the polymerizable compound or the polymerizable composition; and an optically anisotropic article comprising the polymer [in the formula, Y.sup.1 to Y.sup.8 are a chemical single bond, —O—, —O—C(═O)—, —C(═O)—O—, or the like; G.sup.1 and G.sup.2 are a divalent aliphatic group having 1 to 20 carbon atoms, or the like; Z.sup.1 and Z.sup.2 are an alkenyl group having 2 to 10 carbon atoms, or the like; A.sup.1 is a tetravalent aromatic group, or the like; A.sup.2 and A.sup.3 are a divalent alicyclic hydrocarbon group having 3 to 30 carbon atoms, or the like; A.sup.4 and A.sup.5 are a divalent aromatic group having 4 to 30 carbon atoms, or the like; A.sup.x1 and A.sup.x2 are an organic group having 2 to 30 carbon atoms that includes an aromatic ring, or the like; A.sup.y1 and A.sup.y2 are a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; Q.sup.1 and Q.sup.2 are a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; and m and n are 0 or 1]. According to the present invention, a polymerizable compound, a polymerizable composition, and a polymer that have a practical low melting point, exhibit excellent solubility in a general-purpose solvent, can be produced at low cost, and can produce an optical film that achieves uniform conversion of polarized light over a wide wavelength band, and also provide an optically anisotropic article. ##STR00001##

The present invention relates to: a polymerizable compound represented by a formula (I); a polymerizable composition comprising the polymerizable compound and an initiator; a polymer obtained by polymerizing the polymerizable compound or the polymerizable composition; and an optically anisotropic article comprising the polymer [in the formula, Y.sup.1 to Y.sup.8 are a chemical single bond, —O—, —O—C(═O)—, —C(═O)—O—, or the like; G.sup.1 and G.sup.2 are a divalent aliphatic group having 1 to 20 carbon atoms, or the like; Z.sup.1 and Z.sup.2 are an alkenyl group having 2 to 10 carbon atoms, or the like; A.sup.1 is a tetravalent aromatic group, or the like; A.sup.2 and A.sup.3 are a divalent alicyclic hydrocarbon group having 3 to 30 carbon atoms, or the like; A.sup.4 and A.sup.5 are a divalent aromatic group having 4 to 30 carbon atoms, or the like; A.sup.x1 and A.sup.x2 are an organic group having 2 to 30 carbon atoms that includes an aromatic ring, or the like; A.sup.y1 and A.sup.y2 are a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; Q.sup.1 and Q.sup.2 are a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; and m and n are 0 or 1]. According to the present invention, a polymerizable compound, a polymerizable composition, and a polymer that have a practical low melting point, exhibit excellent solubility in a general-purpose solvent, can be produced at low cost, and can produce an optical film that achieves uniform conversion of polarized light over a wide wavelength band, and also provide an optically anisotropic article. ##STR00001##

The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.

The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.

Processes for preparing (((3aR,6aS)-5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)methanone

##STR00001##

are described, which are useful for commercial manufacturing. Said compound is an orexin receptor modulator and may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia and depression.

The present disclosure provides novel ATX inhibitors, and pharmaceutical compositions comprising said inhibitors, as well as methods of treatment comprising administration of said inhibitors.

The present disclosure provides novel ATX inhibitors, and pharmaceutical compositions comprising said inhibitors, as well as methods of treatment comprising administration of said inhibitors.

The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

A series of double-component, bis O.sup.2-aryl diazeniumdiolate derivatives are provided, of which each molecule can release up to four nitric oxide molecules. These compounds show cytotoxic activities to cancer cells, such as human leukemia, breast cancer and lung cancer. Among them, the compound 3 showed the highest specific activity against human leukemia cells.